Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 5/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474782 | 1.00 | GPR3 (0.44) | GPR3AKR1C2AKR1C1KIF11NOTUM | |
| SCHEMBL1275598 | 0.84 | GPR3 (0.44) | GPR3AKR1C2AKR1C1KIF11NOTUM | |
| SCHEMBL29894167 | 0.81 | GPR3 (0.48) | GPR3AKR1C2AKR1C1KIF11MRGPRX4 | |
| SCHEMBL8065084 | 0.81 | GPR3 (0.48) | GPR3AKR1C2AKR1C1KIF11MRGPRX4 | |
| SCHEMBL22714098 | 0.81 | GPR3 (0.48) | GPR3KIF11CYP2C9SCN5ACES1 | |
| SCHEMBL1040929 | 0.79 | GPR3 (0.41) | GPR3AKR1C2AKR1C1KIF11NOTUM | |
| SCHEMBL30628388 | 0.78 | GPR3 (0.46) | GPR3KIF11FFAR4CYP2C9SCN5A | |
| SCHEMBL8461833 | 0.78 | GPR3 (0.46) | GPR3AKR1C2AKR1C1KIF11MRGPRX4 | |
| SCHEMBL17420607 | 0.78 | GPR3 (0.46) | GPR3KIF11FFAR4CYP2C9SCN5A | |
| SCHEMBL10825618 | 0.78 | MRGPRX4 (0.48) | GPR3MRGPRX4FFAR4CYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683044-A | Preparation method and application of asymmetric diaryl trithiophene/selenophene small molecular material | 中国科学院大学 | 2024-03-12 | — | — | CN | disclosed |
| EP-3870295-B1 | NOVEL TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021249800-A1 | SUBSTITUTED [1,2,4]TRIAZOLE COMPOUNDS AS FUNGICIDES | BASF SE (DE) | 2021-12-16 | — | — | WO | disclosed |
| US-20210387996-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| CN-112888480-A | Novel tricyclic compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2021047622-A1 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-18 | — | — | WO | disclosed |
| EP-3226858-B1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2021-02-03 | — | — | EP | disclosed |
| CN-110117284-A | Nitrogen-containing hetero cyclics and its preparation method and application | 江苏奥赛康药业有限公司 | 2019-08-13 | — | — | CN | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| CN-102753558-A | Nitroimidazooxazines and their use in antitubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEV | 2012-10-24 | — | — | CN | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7045529-B2 | Imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-18 | — | — | US | disclosed |
| EP-1244666-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | Bristol-Myers Squibb Pharma Company (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001044248-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | CRH, GPR119, CRHR1 | GPR3 277/4885AKR1C2 2530/4885AKR1C1 2614/4885 |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | GPR3 2347/4885AKR1C2 144/4885AKR1C1 82/4885 |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | GPR3 3683/4885AKR1C2 3428/4885AKR1C1 3336/4885 |
| US-20210387996-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | TOP2B, HAVCR2, SLC10A1 | GPR3 4124/4885AKR1C2 593/4885AKR1C1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.